XLO
Xilio Therapeutics·NASDAQ
--
--(--)
--
--(--)
XLO fundamentals
Xilio Therapeutics (XLO) released its earnings on Aug 14, 2025: revenue was 8.09M (YoY +243.01%), missed estimates; EPS was -2.24 (YoY +33.33%), missed estimates.
Revenue / YoY
8.09M
+243.01%
EPS / YoY
-2.24
+33.33%
Report date
Aug 14, 2025
Earnings Call
7:30 AM on Aug 14, 2025
Meeting link.EPS
Actual | -297.78 | -13.72 | -10.92 | -12.6 | -10.08 | -11.48 | -11.62 | -9.8 | -8.54 | -8.96 | -8.68 | -3.36 | -3.08 | -2.8 | -2.52 | -2.24 |
Forecast | -15.2133 | -15.568 | -14.112 | -10.955 | -12.285 | -10.99 | -12.39 | -12.145 | -11.305 | -8.715 | -1.54 | -3.22 | -3.4533 | -3.0338 | -2.6978 | -1.1032 |
Surprise | -1857.37% | +11.87% | +22.62% | -15.02% | +17.95% | -4.46% | +6.21% | +19.31% | +24.46% | -2.81% | -463.64% | -4.35% | +10.81% | +7.71% | +6.59% | -103.05% |
Revenue
Actual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.36M | 2.28M | 1.72M | 2.92M | 8.09M |
Forecast | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30.00M | 30.00M | 3.30M | 3.30M | 4.40M | 8.21M |
Surprise | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -100.00% | -92.14% | -30.91% | -47.76% | -33.75% | -1.46% |
Earnings Call
You can ask Aime
What does Xilio Therapeutics do and what are its main business segments?Did Xilio Therapeutics beat or miss consensus estimates last quarter?What guidance did Xilio Therapeutics's management provide for the next earnings period?What is Xilio Therapeutics's latest dividend and current dividend yield?What were the key takeaways from Xilio Therapeutics's earnings call?What is Xilio Therapeutics's gross profit margin?What factors drove the changes in Xilio Therapeutics's revenue and profit?What were the key takeaways from Xilio Therapeutics’s earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
